Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions (IDEs)

Draft Guidance for IDE Sponsors, Sponsor-Investigators and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Document issued on June 18, 2015.

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document regarding CDRH-regulated devices, contact the Office of Device Evaluation, Office of the Director, Investigational Device Exemptions (IDE) Staff at 301-796-5640. For questions about this document for CBER-regulated devices, contact the Office of Communication, Outreach and Development at 1-800-335-4709 or 240-402-7800.





U.S. Department of Health and Human Services Food and Drug Administration

Center for Devices and Radiological Health

Center for Biologics Evaluation and Research

29	Preface
30	
31	Additional Copies
32	
33	CDRH
34	Additional copies are available from the Internet. You may also send an e-mail request to CDRH
35	Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 1783
36	to identify the guidance you are requesting.
37	
38	CBER
39	Additional copies are available from the Center for Biologics Evaluation and Research (CBER)
40	by written request from the Office of Communication, Outreach and Development (OCOD),
41	10903 New Hampshire Ave., WO71, Room 3128, Silver Spring, MD 20993-0002, or by calling
42	1-800-835-4709 or 240-402-7800, by email, ocod@fda.hhs.gov, or from the Internet at
43	http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformatio
44	n/Guidances/default.htm.
45	
46	

48			
49	I.	INTRODUCTION	4
50	II.	SCOPE	6
51	III.	INFORMED CONSENT AND IDE DECISIONS	6
52	A.	Informed Consent	7
53	B.	Regulatory Standard for IDE Decisions	8
54	C.	Types of IDE Decisions	10
55	IV.	IDE ASSESSMENT IN THE CONTEXT OF A DEVICE DEVELOPMENT	
56		PATHWAY	12
57	A.	Stages of Device Development	12
58	В.	Applying Benefit-Risk Framework to IDE Decision-Making	13
59	V.	ASSESSING BENEFITS AND RISKS FOR IDE STUDY APPLICATIONS	14
60	A.	Assessment of Risks to Study Subjects	16
61	B.	Assessment of Other Risks Considerations of Investigational Study	20
62	C.	Assessment of Direct Benefits to the Study Subject	21
63	D.	Assessment of Benefits to Others	21
64	E.	Other Factors to Consider When Assessing Benefit-Risk for IDEs	23
65	F.	Overall IDE Benefit Risk Determination	24
66	APPI	ENDIX A – RECOMMENDED GENERAL FRAMEWORK FOR BENEFIT-RISI	K
67		ASSESSMENT	26
68	APPI	ENDIX B – HYPOTHETICAL EXAMPLES OF SUMMARY BENEFIT-RISK	
69		ASSESSMENTS	1
70	APPI	ENDIX C – REFERENCE GUIDE: DESCRIPTION OF INVESTIGATIONAL	
71		DEVICE	8
72	APPI	ENDIX D – GLOSSARY OF RISK MANAGEMENT TERMS	10

I. INTRODUCTION

and those of a sponsor.

FDA is committed to improving U.S. patient access to new devices by strengthening and streamlining the clinical trial enterprise so that medical device clinical trials are conducted in the U.S. in an efficient and cost-effective manner, while maintaining appropriate patient and research participant protections.

The purpose of this guidance is to provide greater clarity for FDA staff and investigational device exemption (IDE) sponsors and sponsor-investigators regarding the principal factors that FDA

Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions (IDEs)

Draft Guidance for IDE Sponsors, Sponsor-Investigators and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

¹ As defined in 21 CFR 812.3, a sponsor is a person or other entity that initiates but does not actually conduct the investigation. A person other than an individual (e.g., a corporation or an agency) which uses one or more of its own employees to conduct an investigation that it has initiated is considered to be a sponsor, not a sponsor-investigator, and the employees are considered to be investigators. A sponsor-investigator is an individual who both initiates and actually conducts, alone or with others, a clinical investigation, i.e., under whose immediate direction the investigational device is administered, dispensed, or used. The term does not include any person other than an individual (e.g., a corporation or agency). The obligations of a sponsor-investigator include those of an investigator

Draft - Not for Implementation

97 considers when assessing the benefits and risks of IDE applications for human clinical studies.

98 Consistent with applicable statute and regulations, FDA will generally disapprove an IDE

application if, among other reasons, "[t]here is reason to believe that the risks to the subjects are

not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained." In many cases, the Agency believes that effective risk management, including the

application of risk controls and risk mitigation measures, can result in a favorable IDE benefit-

risk determination.

FDA recognizes that in assessing risks and anticipated benefits, the medical device total product lifecycle should be considered, and that earlier stages of device development and investigational clinical study are typically associated with greater *uncertainty* (i.e., a lower level of evidence). A primary goal of this guidance is to clarify the factors that FDA considers when assessing risks and anticipated benefits for approving IDE studies, and how uncertainty may be offset by a variety of *risk mitigation* measures which can assure appropriate patient and research participant protections in investigational research settings. For proposed IDE studies, at earlier stages of device development, FDA considers appropriate mitigation measures for anticipated possible risks and unanticipated risks, whereas in later stages risk mitigation focuses increasingly on the most probable risks.

Another important goal of this guidance is to characterize benefits in the context of investigational research, which includes direct benefits to the subject and benefits to others (to the extent they are indirect benefits to subjects or reflect the importance of knowledge to be gained from the study).

As with the benefit-risk framework for evaluating marketing applications, ³ FDA assessment of benefits and risks for an IDE application takes into account the contextual setting in which the study is being proposed, including but not limited to characterization of the disease or condition being treated or diagnosed, the availability of and risks associated with alternative treatments or diagnostics. When available, information characterizing subject tolerance for risk and perspective on benefit may provide useful context during this assessment.

FDA believes use of this benefit-risk framework will facilitate the incorporation of evidence and knowledge from different domains—clinical, nonclinical, and patient—to support a comprehensive, balanced decision-making approach. FDA envisions this will facilitate a common understanding between FDA and sponsors/sponsor-investigators by highlighting which factors are critical in the benefit-risk assessment for a specific application, and clearly explaining how these factors influence FDA's decisions. FDA also believes implementation of this guidance document will improve the predictability, consistency, and transparency of the review process for IDE applications.

² 21 CFR 812.30(b)(4).

³ See e.g., FDA Guidance, <u>Factors to Consider When Making Benefit-Risk Determinations in Medical Device</u> <u>Premarket Approval and De Novo Classifications (March 28, 2012).</u>

http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm267829.htm.

Draft - Not for Implementation

- 137 FDA's guidance documents, including this one, do not establish legally enforceable
- 138 responsibilities. Instead, guidance documents describe the Agency's current thinking on a topic
- and should be viewed only as recommendations, unless specific regulatory or statutory
- requirements are cited. The use of the word *should* in Agency guidance documents means that
- something is suggested or recommended, but not required.

142

143

II. SCOPE

144

- 145 This guidance document explains the principal factors that FDA considers when assessing
- benefits and risks of applications for IDEs for human clinical investigations of certain medical
- devices to determine safety and effectiveness. The approach discussed in this guidance is
- applicable to studies subject to the IDE requirements in 21 CFR part 812, including postmarket
- studies. ⁴ This guidance applies to both diagnostic and therapeutic devices.

150

III. INFORMED CONSENT AND IDE DECISIONS

- The purpose of the IDE regulations, as set forth in 21 CFR part 812, is to encourage, to the extent
- 154 consistent with the protection of public health and safety and with ethical standards, the
- discovery and development of useful devices intended for human use, and to maintain optimum
- freedom for scientific investigators in their pursuit of this purpose. ⁵ 21 CFR part 812 applies to
- all clinical investigations of devices to determine safety and effectiveness with some exceptions.⁶

⁴ In general, IDE applications are required for clinical investigations of significant risk devices to determine safety and effectiveness. 21 CFR 812.2.

⁵ 21 CFR 812.1.

⁶ See 21 CFR 812.2(c), 21 CFR part 812, with the exception of 21 CFR 812.119, does not apply to investigations of the following categories of devices:

⁽¹⁾ A device, other than a transitional device, in commercial distribution immediately before May 28, 1976, when used or investigated in accordance with the indications in labeling in effect at that time.

⁽²⁾ A device, other than a transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to be substantially equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the labeling FDA reviewed under subpart E of part 807 in determining substantial equivalence.

⁽³⁾ A diagnostic device, if the sponsor complies with applicable requirements in 809.10(c) and if the testing: (i) Is noninvasive,

⁽ii) Does not require an invasive sampling procedure that presents significant risk,

⁽iii) Does not by design or intention introduce energy into a subject, and

⁽iv) Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.

⁽⁴⁾ A device undergoing consumer preference testing, testing of a modification, or testing of a combination of two or more devices in commercial distribution, if the testing is not for the purpose of determining safety or effectiveness and does not put subjects at risk.

⁽⁵⁾ A device intended solely for veterinary use.

⁽⁶⁾ A device shipped solely for research on or with laboratory animals and labeled in accordance with 812.5(c).

⁽⁷⁾ A custom device as defined in 812.3(b), unless the device is being used to determine safety or effectiveness for commercial distribution.

Draft - Not for Implementation

FDA approval of an IDE application prior to study initiation is typically required for a clinical 158 investigation conducted in the U.S. of a significant risk device⁸ that is not approved or cleared 159 for the indication being studied. ⁹ An approved IDE application exempts the study sponsor from 160 certain provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (such as certain 161 requirements for a marketing application, good manufacturing practice). However, IDE studies 162 must comply with the applicable requirements set forth in 21 CFR part 812, including 163 164 requirements for informed consent under 21 CFR part 50, labeling of devices for investigational use only, study monitoring, records and reporting, and approval by an Institutional Review Board 165 166 (IRB) in accordance with 21 CFR part 56.¹⁰

167

168

A. Informed Consent

169 170

171

172173

174

175

176177

178

A key tenet of FDA's IDE benefit-risk framework is appropriate protection of human subjects and a key principle of human subject protection in clinical investigations is the informed consent process ¹¹. This process goes beyond obtaining a signature on an informed consent form. The informed consent process provides the prospective subject or his or her legally authorized representative with adequate information about the study, including pertinent information about the investigational device, its risk and benefits, alternatives, and what is expected of the subject in order to participate in the study (e.g., study visits, procedures, maintaining subject diaries). ¹² The subject or his or her legally authorized representative must be given sufficient opportunity to consider whether or not to participate in the clinical study under circumstances that minimize the possibility of coercion or undue influence. ¹³

179 180 181

182

183

184

An informed consent process should allow an individual to decide to accept potential risks associated with a study in exchange for the potential for anticipated benefits to the subjects and the importance of the knowledge to be gained. The informed consent process allows individuals to exercise their personal tolerance of risks as weighed against other factors, including the

- 1. Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;
- 2. Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;
- 3. Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or
- 4. Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

⁷ See 21 CFR 812.2(b) for conditions under which an IDE application is required prior to study initiation.

⁸ As defined in 21 CFR 812.3(m), a significant risk device means an investigational device that:

⁹ See section 520(g) of the Federal Food, Drug and Cosmetic Act (FD&C Act) and 21 CFR part 812.

¹⁰ Section 520(g)(3) of the FD&C Act.

¹¹ See generally, 21 CFR part 50.

¹² See 21 CFR 50.25.

¹³ See 21 CFR 50.20.

Draft - Not for Implementation

reasonably expected benefits and the alternatives to the study.

The informed consent process ensures that each individual makes a determination about study participation after being informed of the study, including the risks and benefits of study participation, and, if applicable, the possibility of receiving no direct benefit. The informed consent regulations in 21 CFR part 50 describe the informed consent aspects of human subject protection in clinical investigations subject to FDA regulations. For example 21 CFR 50.20, states the following:

"Except as provided in 50.23 and 50.24, no investigator may involve a human being as a subject in research unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative."

In addition, 21 CFR 50.25(2) states that the informed consent must include "a description of any reasonably foreseeable risks or discomforts to the subject."

FDA recognizes the public health benefit of permitting well-designed clinical investigations of medical devices to proceed in a timely and efficient manner while ensuring proper subject protections including an appropriate informed consent process. When determining whether to approve an IDE application, FDA considers a variety of factors. FDA seeks to offer flexibility to allow clinical investigations to commence without unnecessary delay, while ensuring that human subjects are adequately protected. (See Section III.C. for a more detailed discussion of human subject protection).

B. Regulatory Standard for IDE Decisions

Under section 520(g)(4)(B) of the FD&C Act, an IDE application may only be disapproved if FDA finds that the investigation does not conform to the procedures and conditions prescribed under regulations. The purpose of the IDE process is "to encourage, to the extent consistent with the protection of the public health and safety and with ethical standards, the discovery and development of useful devices intended for human use and to that end to maintain optimum freedom for scientific investigators in their pursuit of that purpose."¹⁴

- FDA's decision-making for IDE applications was modified with the passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 (Pub. L. No. 112-144).
- 222 Section 601 of FDASIA amended Section 520(g) of the FD&C Act to specify certain situations
- in which FDA cannot disapprove an IDE application. Section 520(g)(4)(C) of the FD&C Act
- states that, consistent with section 520(g)(1), FDA shall not disapprove an IDE application
- because:

_

¹⁴ Section 520(g)(1) of the FD&C Act.

Draft - Not for Implementation

226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245

- the investigation may not support a substantial equivalence or de novo *(i)* classification determination or approval of the device;
- the investigation may not meet a requirement, including a data requirement, (ii) relating to the approval or clearance of a device; or
- an additional or different investigation may be necessary to support clearance or (iii) approval of the device. 15

In accordance with 21 CFR 812.30(b), FDA may disapprove an IDE application for any of the following reasons:

- (1) There has been a failure to comply with any requirement of this part or the act, any other applicable regulation or statute, or any condition of approval imposed by an IRB or FDA.
- (2) The application or a report contains an untrue statement of a material fact, or omits material information required by this part.
- (3) The sponsor fails to respond to a request for additional information within the time prescribed by FDA.
- (4) There is reason to believe that the risks to the subjects are not outweighed by the anticipated benefits to the subjects and the importance of the knowledge to be gained [emphasis added], or informed consent is inadequate, or the investigation is scientifically unsound, or there is reason to believe that the device as used is ineffective.
- (5) It is otherwise unreasonable to begin or to continue the investigation owing to the way in which the device is used or the inadequacy of:
 - (i) The report of prior investigations or the investigational plan:
 - (ii) The methods, facilities, and controls used for the manufacturing, processing, packaging, storage, and, where appropriate, installation of the device; or

(iii) Monitoring and review of the investigation.

253 254 255

256

257

246

247

248

249

250

251

252

Consistent with this regulation, FDA will generally disapprove an IDE application if potential risks of the proposed study are not justified, or if data provided are insufficient to adequately characterize the safety profile of the device such that, based on the data contained in the IDE application, human clinical investigation is not considered reasonable.

258 259 260

261

262

This guidance document provides greater clarity regarding regulatory assessment of:

risks and benefits associated with clinical investigational device use proposed in IDE applications; 16 and

¹⁵ When the objective of a proposed study is to support a marketing application, the sponsor and other stakeholders may benefit from awareness of protocol modifications that FDA believes are needed to achieve this. FDA will convey such considerations to the sponsor to provide greater clarity and predictability. In addition, FDA will convey certain considerations that FDA believes will be important for future submissions related to the proposed investigation. For more information, see Section IV.A of this document and the FDA Guidance, FDA Decisions for Investigational Device Exemption (IDE) Clinical Investigations (Hereinafter, FDA Decisions for IDE Guidance) (August 19, 2014).

¹⁶ 21 CFR 812.30(b)(4).

Draft - Not for Implementation

• inadequacy or uncertainty regarding the clinical or nonclinical data from prior investigations, the proposed study, the manufacturing, transport and storage of a device, or monitoring oversight of the proposed study. ¹⁷

265266

263264

C. Types of IDE Decisions

268269

270

271

272

273

267

FDA regulations¹⁸ provide for three major categories of decision on an IDE application – approval, ¹⁹ approval with conditions, ²⁰ and disapproval. ²¹ Where appropriate, FDA may allow additional flexibility in how outstanding issues can be addressed (i.e., future concerns, study design considerations, contingent approval, ²² staged approval), to allow clinical investigations to commence without unnecessary delay, while ensuring that human subjects are adequately protected. ²³

274275276

277278

279

280

281

282

In some cases, FDA may grant *staged approval*,²⁴ a mechanism that limits the number of human subjects that may be enrolled in the clinical study, of an IDE application. This decision may be used to permit the clinical investigation to begin in a timely manner while maintaining appropriate subject protections. Staged approval may be used when there is significant uncertainty (outstanding questions) regarding benefit-risk profile for the proposed IDE study, which FDA and the sponsor believe can be addressed with data gathered in parallel with enrollment of some limited portion of study subjects. Without this mitigation measure, the benefit-risk profile of the proposed investigation may not support study initiation.

283 284 285

286

287

FDA may grant *approval with conditions* when there are outstanding issues that do not raise concerns that preclude initiation of the proposed clinical investigation, provided that the sponsor addresses the recommended modifications to the study. Resolution of these issues is not required

¹⁷ 21 CFR 812.30(b)(5).

¹⁸ 21 CFR 812.30(a). ¹⁹ If FDA approves an IDE application the sponsor may begin subject enrollment upon receipt of IRB approval and in accordance with the limits described in FDA's decision letter, including the maximum numbers of U.S. subjects and investigational sites. See FDA Decisions for IDE Guidance, page 6.

¹⁹ If FDA approves an IDE application the sponsor may begin subject enrollment upon receipt of IRB approval and in accordance with the limits described in FDA's decision letter, including the maximum numbers of U.S. subjects and investigational sites. See FDA Decisions for IDE Guidance, page 6.

²⁰ If FDA approves an IDE application with conditions, the sponsor may begin subject enrollment upon receipt of IRB approval and in accordance with the limits described in FDA's decision letter, including the maximum numbers of U.S. subjects and investigational sites, and must submit information addressing the issues identified as conditions of approval in FDA's letter within 45 days. See FDA Decisions for IDE Guidance, page 7.

²¹ If an IDE application is disapproved, the sponsor may not initiate enrollment in the clinical investigation until the sponsor submits an amendment to the IDE to respond to the deficiencies identified in FDA's letter and subsequently receives a new letter from FDA granting approval or approval with conditions. See FDA Decisions for IDE Guidance, page 10.

²² See FDA Guidance, <u>Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies</u> (Hereinafter, FDA Early Feasibility Guidance) (October 1, 2013), for discussion of contingent approval.

The FDA Guidance, FDA Decisions for IDE Guidance provides more information. ²⁴ See FDA Decisions for IDE Guidance for more information on staged approvals.

²⁴ See FDA Decisions for IDE Guidance for more information on staged approvals.

Draft - Not for Implementation

prior to initiation of study subject enrollment, with exception of issues related to the informed consent document which must be addressed before enrollment begins, in accordance with 21 CFR part 50 - Protection of Human Subjects.

Initial IDE application approval decisions reflect the benefit-risk profile of the proposed investigation at the time of FDA's assessment. Changes in approval status (e.g., from disapproval) may be appropriate as new information becomes available which:

- changes the understanding of risks and benefits or their associated level of uncertainty;
- changes confidence in risk control or mitigation measures; or
- changes the disease or clinical diagnostic/treatment landscape in a manner which alters the benefit-risk profile of the IDE device relative to alternatives.

If necessary, FDA may take appropriate regulatory actions to protect study subjects, including placing a clinical hold²⁵ on the study. If the study is placed on hold, no additional subjects may be enrolled.

D. Study Design Considerations

Study design has a direct bearing on the knowledge than can be gained from that study. A poorly designed study may produce evidence which leads to false conclusions and have significant negative public health implications. A poorly designed study could produce data which are inconclusive or difficult to interpret and thereby expose subjects to unnecessary or preventable risk.

In contrast, well-designed studies are more likely to produce important knowledge about a device or disease. FDA believes it is most efficient, and consistent with least-burdensome principles, to encourage the conduct of studies which are designed to meet stated objectives. FDA may inform the sponsor of recommended modifications to the study design – Study Design Considerations $(SDCs)^{26}$ – that FDA believes will improve the quality of the information and knowledge generated by the study.²⁷

²⁵ Under section 520(g)(8) of the FD&C Act, FDA can place a study on "clinical hold" when, among other reasons, the device involved represents an unreasonable risk to the safety of the persons who are the subjects of the clinical investigation.

²⁶ The FDA Guidance, FDA Decisions for IDE Guidance provides more information on the topic of SDCs.

²⁷ Consistent with section 520(g) of the FD&C Act, FDA will not disapprove an IDE because the investigational plan for a pivotal study may not support approval or clearance of a marketing application.

Draft - Not for Implementation

322 IV. IDE APPLICATION ASSESSMENT IN THE CONTEXT OF A 323 DEVICE DEVELOPMENT PATHWAY

A. Stages of Device Development

When making IDE benefit-risk assessments, FDA considers: 1) the stage of development of the device, 2) the maturity of the proposed technology, and 3) the availability of non-clinical testing to complement or replace the need for clinical testing.

FDA guidance defines the following device study types: first in human (FIH),²⁸ early feasibility,²⁹ traditional feasibility,³⁰ and pivotal.³¹ In some cases, IDE studies may also be designed for postmarket investigation of marketed products.

The approach to benefit-risk assessment in IDE applications should be tailored to the stage of device development, because device investigations during different stages of development are generally associated with different types of risk, and different levels of uncertainty. Specifically, a greater degree of uncertainty is expected for novel technologies, and at earlier stages of device development, such as first in human or early feasibility trials, while relatively more certainty is expected in traditional feasibility and pivotal trials. At earlier stages, the focus is on appropriate risk mitigation measures for anticipated possible risks and unanticipated risks, whereas in later stages focus shifts increasingly to mitigating the most probable risks. Additionally, early development clinical studies are typically designed to assess initial safety and proof of concept about the proposed device use. Later stage studies, particularly those intended to support future regulatory applications, are typically designed to assess safety and effectiveness outcomes in an intended patient population, with sufficient information to quantify uncertainty in each. IDE benefit-risk assessments should focus on whether a proposed study is well-designed to meet its stated objectives as appropriate to the stage of development for the investigated device.

For IDE benefit-risk determinations throughout all stages of device development, it is also important to recognize that non-clinical data plays a critical role. Medical devices often have attributes that cannot be tested by clinical methods alone and that play a major role in the performance, safety or effectiveness of the device. In some cases, non-clinical testing (e.g., in vitro tests, animal studies, and computer modeling and simulation) can obviate or reduce the need for additional clinical testing to evaluate certain aspects of device design or performance.

-

²⁸ A first in human study is a type of study in which a device for a specific indication is evaluated for the first time in human subjects. See FDA Early Feasibility Guidance, page 6.

²⁹ An early feasibility study is a limited clinical investigation of a device early in development, typically before the device design has been finalized, for a specific indication (e.g. innovative device for a new or established intended use, marketed device for a novel clinical application). See FDA Early Feasibility Guidance, page 6.

³⁰ A traditional feasibility study is a clinical investigation that is commonly used to capture preliminary safety and effectiveness information on a near-final or final device design to adequately plan an appropriate pivotal study. See FDA Early Feasibility Guidance, page 6.

³¹ A pivotal study is a clinical investigation designed to collect definitive evidence of the safety and effectiveness of a device for a specified intended use, typically in a statistically justified number of subjects. See FDA Early Feasibility Guidance, page 6.

Draft - Not for Implementation

Both clinical and non-clinical testing methods may be used to assess the likelihood/probability or severity of a given risk, and/or the success of risk mitigation measures.

For a reference guide of the information FDA considers when assessing benefit-risk in the context of a device development pathway, refer to Appendix A.

B. Applying Benefit-Risk Framework to IDE Decision-Making

A benefit-risk framework is used both for supporting IDE decision-making, as well as decisions related to marketing submissions (e.g., PMA, de novo, and for certain aspects of 510(k) substantial equivalence determinations). Importantly, however, benefit-risk decision-making is fundamentally different for IDE applications because clinical investigations, by their very definition, are research studies with inherent uncertainty regarding the relative benefits and risks of a given device, technology, or treatment.

Therefore, FDA intends to permit appropriate latitude for the conduct of IDE studies within the boundaries of applicable laws and regulations. In considering whether risks outweigh the anticipated benefits to the subjects and the importance of the knowledge to be gained, absence of definitive evidence of benefit or the presence of purely hypothetical risks are not sufficient justification, in and of themselves, to disapprove an IDE application (see Section III.B. of this guidance).

Given the more limited level of evidence typically associated with IDE applications compared to marketing applications – especially for earlier stages of investigation – decisions about IDE applications are made in settings involving relatively greater uncertainty and a lower level of evidence. The inherent uncertainty present in clinical investigations can often be offset by appropriately tailored risk control / risk mitigation measures which can assure appropriate patient and research participant protections in investigational research settings (some forms of risk controls that may be applied to IDE studies are listed in Section V.A.4.). In considering benefits of investigational research, FDA considers direct benefits to the subject and benefits to others (to the extent they are indirect benefits to subjects or reflect the importance of knowledge to be gained).

As with the benefit-risk framework for marketing applications, ³² FDA assessment of benefits and risks for an IDE application takes into account the contextual setting, including characterization of the disease or condition being treated or diagnosed; and the availability of alternative therapies, including their associated benefits and risks. When available, information characterizing subject tolerance for risk and perspective on benefit may provide useful context during this assessment.

³² See FDA Guidance, <u>Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket</u> Approval and De Novo Classifications (March 28, 2012).

http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm267829.htm

Draft - Not for Implementation

V. ASSESSING BENEFITS AND RISKS FOR IDE APPLICATIONS

The approach outlined in this section describes FDA's key considerations when assessing benefits and risks of IDE studies. FDA recommends using a benefit-risk framework to facilitate the incorporation of evidence and knowledge from different domains—clinical, nonclinical, and patient—to support a comprehensive, balanced decision-making approach. The framework should focus on relevant facts, uncertainties, and key areas of judgment to add clarity and predictability to the regulatory process. FDA envisions that these factors will facilitate common understanding between sponsors and FDA by highlighting which factors are critical in the benefit-risk assessment for a specific application, and clearly explaining how these factors should influence FDA's decision.

FDA recommends IDE sponsors provide as part of the IDE application a section that summarizes the key considerations for the IDE benefit-risk assessment. For an outline of the general framework for IDE benefit-risk assessment, please refer to Appendix A. Appendix B contains generic examples of IDE benefit-risk determinations for illustrative purposes.

This guidance is not intended to provide recommendations regarding device-specific data or study requirements.

Patient Preferences

When applying a benefit-risk framework to decisions on IDE applications, FDA's assessment depends on the value assigned to various risks and anticipated benefits to the patients. In the context of a clinical study, anticipated benefits include not only direct benefits to the patient but also societal benefits in terms of knowledge to be gained from the study.

It is important to acknowledge that individual patient preferences vary, and that a patient may not assign the same values to various risks and anticipated benefits as their physician, family member, or other individual. Furthermore, patient preferences vary, both in preferred modality of treatment/diagnostic procedure (often devices are one option to be considered in a treatment care path which may include surgery or medication), as well as in risk tolerance. Some patients are willing to take on higher risks to potentially achieve a small benefit, whereas others are more risk averse. In certain circumstances, some patients may be willing to participate in clinical studies that offer no or limited direct benefit to subjects, but have anticipated societal benefits in advancing medical science.

It may be appropriate to approve an IDE application where only a subset of the eligible study subject population would accept the risks as weighed against the benefits, provided there is enough information and an adequate informed consent process in place for study patients to make informed decisions. However, if, for a certain IDE application, the risks outweigh the anticipated benefits for all subjects, FDA would disapprove the IDE application in accordance with 21 CFR 812.30(b).

Draft - Not for Implementation

Patient preference information, as it relates to the participants in the study, may be particularly informative in helping to assess the trade-offs between risks and benefits in certain challenging device areas. For example:

• life-saving but high-risk devices (e.g., ventricular assist devices (VADs) for end-stage heart failure);

• devices intended to yield improvements in health-related quality of life (e.g., for seizure prevention, sleep apnea);

• devices intended to yield benefits in terms of health(e.g., obesity devices);

• aesthetic devices (e.g., breast implants, wrinkle fillers);

 devices for use in conditions where alternatives include non-device options such as surgical procedures or medical therapy (e.g., minimally invasive alternatives to open surgery).

When available, information characterizing subject tolerance for risk and perspective on benefit may provide useful context for assessing the benefits and risk of a proposed clinical investigation.

Investigational Device Description

Fundamental to an assessment of benefits and risks associated with investigational device use is an understanding of the investigational device itself. 21 CFR 812.25(d) requires that the investigational plan include a:

description of this device (a description of each important component, ingredient, property, and principle of operation of the device and any anticipated changes in the device during the investigation).

Deficiencies related to an incomplete or inadequate investigational device description are the single most common type of non-clinical deficiency in IDE applications that fail to attain full approval. Appendix C lists the device attributes that FDA recommends be included in the IDE application device description section.

Assessment of Risks Associated with Investigational Device Use

The investigational plan shall include a risk analysis which describes and analyzes all *increased risks* to which subjects will be exposed by the investigation, the manner in which these risks will be minimized, a justification for the investigation, and a description of the patient population including number, age, sex, and condition.³³

³³ 21 CFR 812.25.

Draft - Not for Implementation

FDA recommends that IDE sponsors use an accepted method of risk assessment, where appropriate. For example, this guidance incorporates principles from ANSI/AAMI/ISO 14971,³⁴ an FDA-recognized standard which provides a framework for systematically managing risks of medical devices throughout the total product life cycle.

In addition, there are several key concepts which are commonly not well described in IDE applications received by FDA:

• Harms. Specifying how a hazard could lead to clinical sequelae or other harmful event is important because it allows more precise estimation of risk severity and likelihood.

• Likelihood. Focusing on severity of a risk along with likelihood is important for a complete estimation of that risk.

• Residual risk and completeness of risk control. Many identified risks are reduced to an acceptable level through effective risk controls. FDA's benefit-risk assessment of IDE applications focuses on completeness of risk control measures and whether residual risk outweighs anticipated benefits to the subjects.

FDA may disapprove an IDE application if there is reason to believe that the risks to the subjects outweigh the anticipated benefits to the subjects and the importance of the knowledge to be gained.³⁵ Assessment of benefits and risks should not necessarily be made in comparison to the most technologically advanced alternative but rather to commonly used therapies and treatments.

A. Assessment of Risks to Study Subjects

In general, the assessment of risks to IDE subjects focuses on risks whose existence and characteristics are supported by objective scientific evidence. The assessment of risks must include a description and analysis of all incremental risks to which subjects will be exposed by the investigation, and the manner in which these risks will be minimized. While it is not necessary to include specific mitigations for hypothetical risks that are not supported by scientific evidence or risks that are determined to be negligible due to a low probability of occurrence and low severity of harm, it is helpful to identify all possible risks in the risk assessment and include information on how the level of risk was determined.

Relationship between Hazards and Harm³⁷

Risk assessment involves describing the relationships between a hazard (a potential source of harm) and the ultimate consequences in terms of physical injury or damage. As part of FDA's

_

^{34 &}quot;Medical Devices—Application of risk management to medical devices" ANSI/AAMI/ISO 14971:2007/(R)2010.

³⁵ 21 CFR 812.30(b)(4). ³⁶ 21 CFR 812.25.

³⁷ See Appendix D for a glossary of risk management terms.

Draft - Not for Implementation

518 IDE decision-making, this relationship should specifically describe the foreseeable sequences of 519 events, hazardous situations, and associated possible harm. This may include:

- the initiating hazard, failure mode, or circumstance;
- the sequence of events that could lead to a hazardous situation occurring;
- the likelihood of such a situation arising;
- the likelihood that the hazardous situation leads to harm;
- the nature of the harm that could result.

524525526

520

521

522

523

The extent of risk(s)/harm(s) associated with an IDE study is assessed by taking into account the following factors, individually and in aggregate:

527528529

A.1 Type(s) of risk(s), including severity: The various risks, including the severity of the risk, assumed by the subject from participation in the investigation should be considered. These include:

531532533

534

535

536

530

o **Basic Safety** – protection against physical hazards, which should be addressed and mitigated with a reasonable level of certainty. For example, an active device should not be unsafe from an electrical safety perspective (e.g., the devices should not deliver an unintended electrical shock and surface temperature increases should not unintentionally burn the patient or operator).

537538539

O Device-related serious adverse events – events attributable to the investigational use of the device which produce an injury or illness that is life-threatening, results in permanent impairment or damage to the body, or requires medical or surgical intervention to prevent permanent harm to the body.

541542

540

Device-related non-serious adverse events

543544

Procedure-related complications due to the investigation – This includes not
just the device use but risks related to the investigation itself to which the subject
would otherwise not be exposed, e.g. risk of anesthesia during procedures
involving an investigational device.

546547548

549

545

Risks associated with the study itself – risks the subject may be exposed to that do not directly result from use of the device and would not be expected as part of usual care outside of the investigational setting. Examples include additional procedures (such as medical imaging) for ascertainment of study endpoints.

550551552

553

554

555

556

Risk from false-positive or false-negative results for diagnostics – if a diagnostic device gives a false-positive result, the subject might be exposed to risks associated with unnecessary additional diagnostic procedures and additional tests, or potential unnecessary treatment, as well as the ramifications of diagnosing a potentially incorrect disease. If a false-negative result is given, the subject might not receive effective treatment (thereby missing benefits that treatment would confer), or might not be diagnosed with the correct disease or condition.

557558559

560

561

562

A.2 Likelihood or probability of risk(s):

Various approaches are commonly employed to estimate probabilities of risks including but not limited to: use of relevant historical data; prediction of probabilities of risk using

Draft - Not for Implementation

analytical or simulation techniques; use of experimental data from prior investigations; reliability estimates; production data; post-production information; and use of expert judgment. The use of multiple approaches may be considered as this might serve to increase confidence in the results. During earlier development stages, greater uncertainty may exist around these estimates, in which case it may be useful to consider a qualitative approach to risk probability analysis.³⁸

The likelihood or probability of risk(s) includes the likelihood of the hazard resulting in a harmful event. If known, this includes the number of harmful events per patient or the number of harmful events per unit of time, the proportion of the intended population that would be expected to experience a harmful event, as well as the likelihood of a given subject or study group experiencing a harmful event. FDA considers whether an event occurs once or repeatedly in assessing the probability of risks.

A.3 Duration of risk(s): Some studies expose subjects to temporary, minor harm; some can cause repeated but reversible harm; others can cause permanent, debilitating injury. Duration (i.e., how long the adverse consequence lasts) should be considered along with severity of risk, as described in above in A.1.

A.4 Risk Management³⁹

Risk Management provides a summary and assessment of any efforts that could help to mitigate the identified safety concerns, or assure that device use is directed to those participants for whom the risk is considered acceptable because it does not outweigh the potential for benefit.

Risk control measures (including risk mitigation efforts) should be applied, where appropriate, to reduce the likelihood and severity of harm to study subjects and improve the benefit-risk profile of the proposed IDE study. Risk control measures are intended to reduce the risk to an acceptable level. Sponsors should conduct an initial determination regarding which risk controls are appropriate for their proposed IDE study. Benefit-risk assessment for IDE decisions should focus on residual risk, and whether residual risk has been reduced to acceptable levels relative to the anticipated benefits to the subjects. The sponsor must provide in the IDE application a clear justification for the investigation, having considered risks for the intended study population and the manner in which those risks will be minimized.⁴⁰

Risk mitigation may include device design features/modifications, protective measures (e.g., study design features), and communication of safety information (e.g., training of

³⁸ Such an analysis may include qualitative or semi-quantitative probability levels when the probability has not or cannot be precisely determined, but is known or expected to be within an estimated range. (See ISO 14971, Section D.3 for more information).

³⁹ For additional information on risk management for medical devices, refer to ISO 14971.

⁴⁰ 21 CFR 812.25.

Draft - Not for Implementation

502	investigational staff). Forms of risk controls that may be applied to IDE studies may
503	include but are not limited to:
504	
505	Safety by Design
506	
507	 Device design features and/or modifications
508	
509	Protective Measures
510	
511	 Physical protective measures (e.g., user & subject radiation shielding)
512	 Preparation and readiness of personnel and equipment for anticipated adverse
513	events (e.g., crash carts)
514	• Study design ⁴¹
515	 Staged enrollment with limited initial human subject exposure and
516	interim pre-specified subject safety assessment (e.g., IDE staged
517	approval)
518	 Staged/graded exposure to device intervention (e.g., low level
519	stimulation before high level stimulation)
520	 Pre-specified clinical management of potential adverse events; more
521	frequent reporting
522	 Pre-specified monitoring of study conduct, particularly for aspects
523	critical to safety
524	 Pre-specified stopping rules or guidelines
525	 Performance of study at trained or specialized sites or investigators meeting
526	certain criteria (e.g., multidisciplinary heart team).
527	• Study oversight
528	 Investigational review board/ethics oversight
529	o Use of a Clinical Events Committee, Data Monitoring Committee /
530	Data Safety and Monitoring Board, or other Quality by Design features
531	o IDE Progress Reports
532	o Clinical Hold Authority
533	• Adverse Event reporting 42
534	o More frequent reporting of serious adverse events (e.g., after each
535	occurrence, monthly, quarterly, annually)
636	o Accurate reporting of adverse events, including the timing and clinical
637	context and a description of any medical interventions that were
638	provided and the associated outcomes
539	Communication of sofety information 43
540	Communication of safety information ⁴³

In some cases, it may be appropriate to narrow the study population to a subset where the benefit-risk profile is more favorable (e.g., limit high risk novel therapy to treatment-refractory patients). See Section A.5 – Residual risk evaluation.
⁴² See 21 CFR 812.150.

Draft - Not for Implementation

641		
642		 Informing study subjects about reasonably foreseeable risks of study
643		participation
644		 Communication among study sites regarding safety information (e.g.,
645		investigator and study coordinator calls)
646		 Communicating safety information with the IRB overseeing the study to
647		determine whether any additional human subject protection measures are
648		needed.
649		
650		Note that the preferred hierarchy of risk mitigation is to first attempt to eliminate the risk
651		then if this is not possible, to design and implement protective measures, and
652		communicate the residual risk to patients and operators such as by labeling.
653		
654		A.5 Residual risk evaluation
655		After risk control measures are applied, the following measures may be considered when
656		evaluating any residual risk, particularly in cases where there are substantial risks
657		associated with the study:
658		
659 660		 Risk communication and disclosure of residual risk during the informed consent process
661		 Consideration of subject perspective on assuming risk relative to anticipated
662		benefit
663		• Performance of initial limited study in subjects most likely to experience benefits
664		• Select a participant subset where the benefit-risk profile is more favorable (e.g.,
665		treatment-refractory patients)
666		
667	B .	Assessment of Other Risks Considerations 44 of Investigational Study
668		
669		B.1 Risks related to study data and benefit of knowledge to be gained —
670		Risk of drawing a false conclusion based on clinical data obtained
671		• Risk of data which are inconclusive or difficult to interpret ⁴⁵
672		
673		B.2 Risks to others – Certain investigations may involve risks to others, in which case
674		these risks should be considered. For example:
675		Risk of radiation exposure of health care practitioner
676		If treated subjects become drowsy while operating a vehicle

⁴³ All research includes some risk. After taking appropriate steps to mitigate risk through device design features/modifications and protective measures, it is important to communicate relevant safety information about residual risks.

⁴⁴Consistent with section 520(g)(4)(B) of the FD&C Act, FDA may consider these risks in protection of the public health and safety. FDA review of these risk considerations will focus on appropriate mitigation measures to control

⁴⁵ Refer to Section III.D. for further discussion on this point.

Draft - Not for Implementation

C. Assessment of Direct Benefits to the Study Subject

In general, the assessment of anticipated benefits to IDE subjects does not include purely hypothetical benefits, and instead focuses on those direct benefits whose existence and characteristics are supported by objective scientific evidence. FDA's assessment of anticipated benefits of study participation includes the direct benefits to the subject — benefits that may be realized by the subjects participating in the research, including:

 C.1 Type of benefit(s) – examples include but are not limited to the device's anticipated impact on clinical management, subject health, and subject satisfaction in the target population, such as improving clinical management and quality of life, reducing the probability of death, aiding improvement of subject function, reducing the probability of loss of function, and providing relief from symptoms. For diagnostics, an anticipated benefit may be due to its ability to identify a specific disease and therefore prevent its spread, predict future disease onset, provide earlier diagnosis of diseases, or identify participants more likely to respond to a given therapy.

C.2 Magnitude of the benefit(s) – determined by the anticipated change in subjects' condition or clinical management, or as determined by an improvement or worsening of the endpoint. Variation in the magnitude of the benefit across a population may also be considered.

C.3 Probability of the participant experiencing one or more benefit(s) – based on the evidence provided from prior investigations, it is sometimes possible to predict which subjects may be more or less likely to experience a benefit. In other cases, however, particularly at earlier stages of device development, it may not be possible to assess the probability of a participant experiencing one or more benefits or identifying subgroups most likely to experience a benefit.

C.4 Duration of effect(s) (i.e., how long the benefit can be expected to last for the participant) – some treatments are curative, whereas, some may need to be repeated frequently over the patient's lifetime. To the extent that it is known, the duration of a treatment's effect may directly influence how its anticipated benefit is defined. Treatments that must be repeated over time may introduce greater cumulative risk, or the benefit experienced may diminish each time the treatment is repeated.

D. Assessment of Benefits to Others

In addition to assessing the anticipated direct benefits to IDE subjects, an IDE benefit-risk assessment also includes a consideration of the anticipated benefits to others (to the extent they are indirect benefits to subjects or reflect the importance of the knowledge to be gained).

Draft - Not for Implementation

A required element of the informed consent is a description of any benefits to the subject *or to others* [emphasis added] which may reasonably be expected from the research. ⁴⁶ Benefits to others that may also indirectly benefit the subjects include benefits to caregivers or family members.

A benefit to others of an investigational study is the "importance of the knowledge to be gained." This is not a direct benefit to the subject, but rather is considered a societal benefit in terms of increasing the understanding of a disease condition and potential treatment or diagnostic applications. This benefit is unique to research and does not apply to marketing applications. A greater degree of uncertainty about the benefits and risks of study participation typically exists in IDE submissions, and one should consider the possibility that study subjects will receive no direct benefit from study participation. However, subjects may still be willing to participate because of the indirect benefits, such as the importance of the knowledge to be gained. Studies which are well-designed may be considered to have greater benefits in this regard, because it generates knowledge that can inform safe use and may lead to earlier patient access to high quality, safe and effective devices. ⁴⁸

In assessing an IDE study for the importance of the knowledge to be gained, a key consideration is the likelihood that the study will yield generalizable knowledge about the disorder or condition being studied. There are additional safeguards for the inclusion of children in clinical investigations that are likely to yield generalizable knowledge about the subjects' disorder or condition, but that involve greater than minimal risk with no prospect of direct benefit to individual subjects. ⁴⁹

Finally, studies which are well-designed may be considered to make greater contributions to the knowledge to be gained, as they are more likely to yield useful information and meaningfully increase patient access to reasonably safe and effective devices.

⁴⁶ 21 CFR 50.25(a)(3).

⁴⁷ 21 CFR 812.30(b)(4).

⁴⁸ Consistent with section 520(g) of the FD&C Act, FDA will not disapprove an IDE because the investigational plan for a pivotal study may not support approval or clearance of a marketing application.

⁴⁹ In accordance with 21 CFR 50.53, any clinical investigation within the scope described in 21 CFR 50.1 and 21 CFR 56.101 in which more than minimal risk to children is presented by an intervention or procedure that does not hold out the prospect of direct benefit for the individual subject, or by a monitoring procedure that is not likely to contribute to the well-being of the subject, may involve children as subjects only if the IRB finds that:

⁽a) The risk represents a minor increase over minimal risk;

⁽b) The intervention or procedure presents experiences to subjects that are reasonably commensurate with those inherent in their actual or expected medical, dental, psychological, social, or educational situations;

⁽c) The intervention or procedure is likely to yield generalizable knowledge about the subjects' disorder or condition that is of vital importance for the understanding or amelioration of the subjects' disorder or condition; and (d) Adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in 50.55.

Draft - Not for Implementation

E. Other Factors to Consider When Assessing Benefit-Risk for IDE Applications

The assessment of benefits and risks for an IDE study takes into account the uncertainty surrounding the knowledge and available evidence, the contextual setting in which the study is being proposed, including characterization of the disease or condition being treated or diagnosed, and availability of alternatives and risks associated with them. When available, information characterizing subject tolerance for risk and perspective on benefit may provide useful context during this assessment.

E.1 Characterization of the disease: The treated or diagnosed condition, its clinical manifestation and severity (e.g., temporary or permanent loss of function), how it affects the subjects who have it, how and whether a diagnosed condition is treated, and the condition's natural history and progression (i.e., does it get progressively better or worse for the subject and at what expected rate) are all important factors that FDA considers when characterizing a disease and assessing benefits and risks. For instance, conditions with more severe symptoms and natural course, relatively fewer and less effective treatment options, and less chance of responding to current treatment options, may warrant tolerating greater risk in a study.

E.2 Availability of alternatives: When characterizing the availability of alternatives, important factors that FDA considers are treatment (or diagnostic) options, treatment strategy (if applicable, such as for chronic diseases) and the safety and effectiveness of alternatives including the potential for adverse events. If alternative therapies (or diagnostic options) exist, are effective for the subject population, and are associated with relatively fewer adverse events, then subjects may not tolerate a higher degree of risk of study participation. Assessment should not necessarily be made in comparison to the most technologically advanced alternative but rather to commonly used therapies and treatments.

E.3 Subject tolerance for risk and perspective on benefit: Risk tolerance varies among subjects, and this will affect individual subject decisions to participate in a study. When evaluating benefits and risks, FDA recognizes that tolerance for risk and a subject-centric assessment of risk may reveal reasonable individuals who are willing to tolerate a high level of risk to achieve an anticipated benefit, especially if that benefit results in an improvement in quality of life or achieves societal benefit from knowledge gained. In addition, a thorough informed consent process serves to assure that prospective subjects are informed of, among other information, the risks and benefits of study participation, and agree to the risks of study participation given other factors, including the potential benefits.

E.4 Uncertainty: There is always some uncertainty when weighing benefits and risks prior to clinical study conduct. However, the degree of certainty is a factor we consider when assessing benefit-risk for IDE applications.

Draft - Not for Implementation

- Quality of prior nonclinical and clinical investigations: Well-conducted nonclinical and clinical prior investigations can help reduce uncertainty, particularly related to identified potential hazards. However, poor study design or conduct, or inadequate analysis of prior study data, can produce data which are inconclusive or difficult to interpret.
- Predictive capability of evidence from prior investigations: The ability of the nonclinical testing and prior clinical experience to predict clinical performance in the proposed study is an important consideration, as is the generalizability of early results to the intended study and user population. For example, if the device requires in-depth user training or specialization, the clinical study should be designed to address this issue to assure appropriate risk mitigation. It is important to distinguish between purely hypothetical risks, actual hazards, and the likelihood of subject harm.
- Different uncertainty considerations at different stages of development:

 Different questions of uncertainty may arise at different stages of study. A higher level of uncertainty is expected and may be acceptable in the early stages of device development. Generally, while the types of uncertainty (and questions to be answered) varies across stage of investigation and development, the overall degree of uncertainty of risks and benefits should decline as more data are collected throughout device development and exploration. Refer to Section IV.A. for more information.

E.5 Least burdensome study design: When considering elements of study design, incorporating additional elements often involves trade-offs in terms of time, cost and practicality of study conduct, which may affect other aspects of clinical trial start-up, such as IRB approval and feasibility of subject enrollment. While FDA does not consider cost when deciding to approve an IDE application, the potential impact of study design elements on trial start-up, IRB approvability, and feasibility of subject enrollment should be considered.

F. Overall IDE Benefit Risk Determination

Consistent with applicable statute and regulations, FDA may disapprove an IDE application if, among other reasons, there is reason to believe that the risks to the subjects outweigh the anticipated benefits to the subjects and the importance of the knowledge to be gained. In many cases, the Agency believes that effective risk management, including the application of risk controls and risk mitigation measures, can reduce the residual risk and result in a favorable IDE benefit-risk determination.

FDA believes that the use of a common framework and structured approach to assessing IDE benefits and risks will facilitate the submission not only of relevant evidence and knowledge but also a clear rationale for why the submitted information is sufficient to justify the initiation of the

proposed study. Application of the factors listed in this guidance document can ultimately
improve the predictability, consistency, and transparency of FDA's IDE decision-making,
resulting in the strengthening and streamlining of the clinical trial enterprise in the U.S. so that
medical device clinical trials are conducted in an efficient and cost-effective manner, while
maintaining appropriate patient and research participant protections.



841 842	APPENDIX A – RECOMMENDED GENERAL FRAMEWORK FOR BENEFIT-RISK ASSESSMENT
843	
844	FDA recommends IDE sponsors provide as part of the IDE application a section that
845	summarizes the key considerations in the IDE benefit-risk assessment. The benefit-risk summary
846	should provide a concise synopsis and may reference relevant sections in the IDE application
847	where supporting information and evidence can be found. The intent of this summary is not to
848	provide an all-encompassing summary of the benefit-risk assessment, but rather to focus on
849	those items which are likely to significantly affect FDA's decision or recommendation.
850	
851 852	FDA recommends that the benefit-risk summary address the following key elements:
853	1. CONTEXT OF THE PROPOSED INVESTIGATION
854 855	Provide a summary of the disease or condition to be treated or diagnosed, a description of
856	the device in the context of currently available treatment or diagnostic options, and a brief
857	description of the investigation (its objective and design).
858	description of the investigation (its objective and design).
859	2. ASSESSMENT OF RISKS OF THE PROPOSED INVESTIGATION
860	2. FISSESSIVELY OF RISING OF THE THOTOSES INVESTIGATION
861	A summary of the key risk elements identified in Section 5 of the guidance including risk
862	characterization, risk control measures, and residual risk.
863	
864	3. ASSESSMENT OF BENEFITS OF THE PROPOSED INVESTIGATION
865	
866	A summary of the key benefits of the proposed investigation as identified in Section 5 of
867	the guidance including direct benefits to study subjects of the proposed investigation and
868	benefits to others (to the extent they are indirect benefits to subjects or reflect the
869	importance of the knowledge to be gained).
870	
871	4. CONSIDERATION OF PATIENT PREFERENCE INFORMATION
872	
873	A summary of available patient preference information, if any. If none, state that none
874	was provided.
875	5 ACCECCMENT OF UNCEDTAINTY
876 877	5. ASSESSMENT OF UNCERTAINTY
878	Summarize key sources of uncertainty in the available evidence and proposed
879	investigation as identified in Section 5 of the guidance, and provide a rationale for why
880	the level of uncertainty is acceptable for the proposed investigation.
881	and level of uncertainty is acceptable for the proposed investigation.
882	6. CONCLUSIONS
883	
884	Summarize how the consideration of the factors discussed in this summary justify the
885	decision to proceed with human clinical investigation.

886 887	APPENDIX B – HYPOTHETICAL EXAMPLES OF SUMMARY BENEFIT-RISK ASSESSMENTS
888	
889	FDA recommends IDE sponsors provide as part of the IDE application a section that
890	summarizes the key considerations in the IDE benefit-risk assessment. The benefit-risk summary
891	should provide a concise synopsis and may reference relevant sections in the IDE application
892	where supporting information and evidence can be found (see Appendix A for details).
893	
894	The examples below are simplified and offered for illustrative purposes only. The decisions
895	described in these examples are intended to demonstrate how to present the factors described in
896	this guidance when making benefit-risk assessments and how FDA may analyze these factors.
897	Example 1 – Pivotal study proposal for a device to treat a life-threatening condition with
898	poor alternative treatments
899	CONTEXT OF THE PROPOSED INVESTIGATION
900	A company has developed a permanently implantable device to treat a disease that affects adults
901	and is associated with a high risk of mortality. Generally there is progression to advanced disease
902	within 12 months, and 30% of patients die within 24 months. While pharmacological treatments
903	are available, they primarily offer only transient symptomatic relief and are associated with
904	significant complications. The sponsor proposes a prospective randomized study to assess the
905	use of a device to treat the condition compared with a standard pharmacological treatment.
906	ASSESSMENT OF RISKS OF THE PROPOSED INVESTIGATION
907	The device has risks associated with both the surgical procedure required for implantation and
908	long-term use. These risks have been evaluated in animal studies and a small short-term clinical
909	feasibility study. The risks are potentially severe and the likelihood of occurrence is only
910	partially understood.
911	Based on the information gained from the previous non-clinical and clinical studies, the sponsor
912	has proposed minor changes to the implant procedure that may reduce the risk. Additional risk
913	mitigation procedures include: careful subject selection, the use of specialized/experienced study
914	investigators, subject monitoring procedures, and use of an independent Data Safety and
915	Monitoring Board.
916	ASSESSMENT OF BENEFITS OF THE PROPOSED INVESTIGATION
917	Initial data from the previous nonclinical and clinical studies demonstrated the potential for
918	clinically relevant reductions in morbidity and mortality from the condition, although the amount
919	of data available is limited and a control group was not used. In addition, the long-term
920	effectiveness of the device has not yet been explored.
921	
922	
923	

924	CONSIDERATION OF PATIENT PREFERENCE INFORMATION
925	
926	Given the lack of effective current treatments and the significant morbidity and mortality
927	associated with the disease, patients are expected to have a high risk tolerance for considering
928	potential new treatments. However, definitive patient preference data are lacking.
929	ASSESSMENT OF UNCERTAINTY
930	The greatest degree of uncertainty is regarding the anticipated benefits of the device. While the
931	nonclinical and clinical feasibility study data are encouraging, it is unclear whether clinically
932	relevant benefits will be demonstrated in a controlled study with long-term follow-up. There is
933	also uncertainty regarding the risk profile, and whether the changes in the implant procedure and
934	implementation of the other mitigation strategies will be effective.
935	CONCLUSIONS
936	This study is characterized by a significant degree of risk and a high level of uncertainty
937	regarding the anticipated benefits. However, given the lack of effective alternative treatments,
938	the risks associated with those treatments, the consequences of ineffective treatment, and that the
939	benefits and risks of the device have been reasonably characterized in non-clinical and feasibility
940	clinical studies, FDA is likely to approve the pivotal IDE study.
941	If current treatments were more effective at controlling or curing the disease process, if the
942	disease process were more benign, the benefit-risk assessment might be unfavorable. If
943	feasibility clinical study data were not available, there would be a significantly higher degree of
944	uncertainty regarding anticipated benefits.
0.45	
945	

946 947	Example 2 – Feasibility study proposal for a device to treat a life-limiting condition with reasonable alternative treatments
948	CONTEXT OF THE PROPOSED INVESTIGATION
949 950 951 952	A company has developed an absorbable device to treat a condition associated with modest pain and functional limitations, but not increased mortality. Several reasonably effective permanently implantable device alternatives exist, although they are associated with chronic adverse events that in some patients require surgical revision, device removal, or replacement.
953 954	The sponsor proposes a prospective non-randomized feasibility study to provide a preliminary assessment of the safety and potential for benefit of an absorbable device.
955	ASSESSMENT OF RISKS OF THE PROPOSED INVESTIGATION
956 957	Compared to the currently available alternatives there are two primary unaddressed risks associated with this device.
958 959 960 961 962	The first risk is that the device is comprised of new materials that have not been fully characterized and may have significant toxicities. While the materials are similar to those used in other devices, the differences in formulation and processing for this device have the potential to lead to an unacceptable safety profile. The biocompatibility of the device can be addressed with additional nonclinical testing that was not provided by the sponsor.
963 964 965 966 967 968	The effectiveness of the device is dependent on the concept that preservation of structural integrity is only needed during the acute healing phase of the condition and that the device degradation profile is consistent with the healing timeline. However, there is a risk that premature device degradation will result in the loss of structural integrity prior to complete healing and subsequent reoccurrence of the condition. Assessment of the chronic performance of the device will likely require clinical evaluation.
969 970 971	The sponsor has not specified any clinical mitigation strategies for the study. To address the biocompatibility concern, the sponsor states that the similarity in materials to other absorbable devices is sufficient mitigation.
972	ASSESSMENT OF BENEFITS OF THE PROPOSED INVESTIGATION
973 974	There is theoretical support for the concept that an absorbable device could reduce the chronic adverse events associated with the currently available devices while maintaining effectiveness.
975	CONSIDERATION OF PATIENT PREFERENCE INFORMATION
976 977	The sponsor has provided a small survey regarding patient preference. The survey indicates that some patients are satisfied with the currently available devices. However, there is a modest level

978 979	of interest in novel technologies that could reduce the potential need for future surgery for device removal or replacement.
980	ASSESSMENT OF UNCERTAINTY
981 982	There is considerable uncertainty regarding whether this absorbable device provides sufficient structural integrity over an appropriate timeframe to support chronic healing of the condition.
983	There is also considerable uncertainty regarding the potential toxicity of degradants.
984	CONCLUSIONS
985 986 987 988 989 990	This device is intended to treat a condition associated with modest pain and discomfort for which there are reasonable alternatives currently available. The new materials raise biocompatibility concerns which may result in unacceptable risks for subjects which can and should be addressed with nonclinical testing that the sponsor has not provided. There does not appear to be a strong basis for allowing the clinical study to proceed until the biocompatibility data are provided, as FDA does not concur that the claim of similarity in materials is adequate to address this concern. Therefore, FDA would likely not approve this study until these data are provided and found to be
992	supportive of an acceptable biocompatibility profile.
993	
994	

Draft - Not for Implementation

995 996 997	Example 3 – Early feasibility study proposal for a device to treat a life-threatening condition without an alternative treatment option
998	CONTEXT OF THE PROPOSED INVESTIGATION
999	The condition affects adults and is associated with a high risk of morbidity and mortality.
1000 1001 1002	No effective treatment alternative exists for patients with the advanced form of the disease. Treatments that are successful for patients with less severe forms of the disease have failed in patients with advanced disease.
1003 1004	The sponsor proposes an early feasibility study to provide proof of principle and initial clinical safety data for the use of a device to treat the condition.
1005	ASSESSMENT OF RISKS OF THE PROPOSED INVESTIGATION
1006 1007 1008 1009 1010 1011 1012 1013	This intervention has risks associated with both the procedure as well as the potential for long-term adverse effects. The procedural risks have been evaluated in an animal study. In addition, information can be leveraged from the clinical experience with a similar device for a different intended use. With available leveraged information and an understanding of the device design concept, the types of risks are known, but the frequency and severity are unknown. In cases where patient characteristics (e.g., age, gender, or other key variables) are not comparable for the new intended use, the extent to which this previous clinical experience can be leveraged may be more limited.
1014 1015	The sponsor has proposed several clinical study mitigation strategies to minimize the frequency and severity of risks to study subjects including the following:
1016 1017	• use of study sites that have sufficient expertise and resources to manage adverse events and provide appropriate additional therapies if needed;
1018 1019	 identification of qualified investigators with adequate training to conduct the early feasibility study;
1020 1021 1022	 implementation of an informed consent process which adequately conveys to potential subjects the high degree and seriousness of both known and unknown risks and the low likelihood of direct benefits;
1023 1024	• a plan to capture human factors information during the course of the study to modify the procedures or device as necessary based on the information obtained prior to the

treatment of additional participants;

1026 1027	• limiting the sample size to a reasonable number for an early feasibility study (e.g., 5-10 initial subjects);
1028	• frequent follow-up assessments to monitor subject safety and device effectiveness;
1029 1030	• timely reporting of serious adverse events (i.e., after each occurrence rather than only in a periodic progress report);
1031 1032	 timely reporting of device performance parameters, which help determine whether the device functions as intended;
1033 1034 1035 1036	 non-sequential enrollment, that is, initial device use in subjects with more favorable anatomical characteristics as compared to the population otherwise eligible for the early feasibility study (i.e., selecting subjects that meet study eligibility requirements but do not have anatomic features that may increase the difficulty of device use); and
1037 1038	 a pre-specified plan for periodic participant outcome assessments and reporting prior to enrollment of additional participants (i.e., after each use of the device).
1039	ASSESSMENT OF BENEFITS OF THE PROPOSED INVESTIGATION
1040 1041 1042	Initial data from the previous nonclinical studies, with the available leveraged information, suggest the potential for clinically relevant reductions in morbidity and mortality from the condition, despite the potential for procedure-related and long-term adverse effects.
1043	CONSIDERATION OF PATIENT PREFERENCE INFORMATION
1044 1045 1046 1047	Given the lack of an effective alternative treatment and the morbidity and mortality associated with the condition, patients are expected to have a high risk tolerance for considering potential new treatments. However, no definitive data have been provided by the sponsor to support this expectation.
1048	ASSESSMENT OF UNCERTAINTY
1049 1050 1051 1052	Due to the novelty of the device and procedure and the lack of a nonclinical model to predict the clinical safety and effectiveness of the device, there is a high degree of uncertainty regarding the device, including the initial safety, the long-term adverse effects of the treatment, and the anticipated benefits.
1053	CONCLUSIONS
1054 1055 1056	Potential study subjects have failed conventional treatments that can be beneficial to patients with less severe cases. The proposed study is characterized by a significant degree of uncertainty, given the early phase of device development and the novelty of the proposed device

1057 1058	and procedure. Information available on a similar device from a different intended use and from an animal study provide some assurance that catastrophic failures would not be anticipated
1059	during the early feasibility study. Conducting additional nonclinical testing is unlikely to provide
1060	information to decrease the level of uncertainty.
1061	Considering that: (1) the proposed device treats a severe disease for which there is no alternative
1062	treatment; (2) information is available from the clinical experience with a similar device for a
1063	different intended use to suggest that catastrophic failures will not occur; (3) there is reason to
1064	believe that patients may benefit from treatment with the device; and (4) additional nonclinical
1065	testing will not provide the information needed to advance the device design, FDA is likely to
1066	approve the early feasibility study IDE.
1067	

Draft - Not for Implementation

APPENDIX C – REFERENCE GUIDE: DESCRIPTION OF INVESTIGATIONAL DEVICE

Fundamental to an assessment of benefits and risks associated with investigational device use is an understanding of the investigational device itself. 21 CFR 812.25(d) requires that the investigational plan include a:

description of this device (a description of each important component, ingredient, property, and principle of operation of the device and any anticipated changes in the device during the investigation).

Deficiencies related to an incomplete or inadequate investigational device description are the single most common type of non-clinical deficiency in IDE applications that fail to attain full approval. This Appendix lists the device attributes that CDRH recommends be included in the IDE device description.

The investigational device description should include an explanation of how the device functions, the scientific concepts that form the basis for the device, and the significant physical and performance characteristics of the device, such as device design, material used, and physical properties. A complete description of the device may be facilitated by the submission of engineering schematics or other figures. If the device consists of multiple components, a diagram identifying how the different components of the device system work together may be beneficial. The device description should also include a discussion of the physical specifications, dimensions and mechanical tolerances of the investigational device.

CDRH recognizes that an IDE application may be approvable even if there is uncertainty regarding some elements of the device description, depending on the novelty of the device, its stage of development, and its intended use. In addition, in some cases, such as sponsor-investigator initiated studies, the IDE sponsor may not have access to all recommended elements.

In general, it is recommended that the investigational device description include the following details or provide a rationale for why information concerning the specified element is not needed or does not apply:

Device Identification:

 List all device components (e.g., catheter, cable wire, leads, sizing tools, delivery system, etc.)

 List all models to be used in the investigation and briefly explain the differences among models

o Brief Written Description of the Device:

	, , , ,
1113	 Explanation of how the device works/principle of operation
1114	 Mechanism of action, if known
1115	 Key performance specifications and manufacturing tolerances of the
1116	device
1117	 Key device features/characteristics (address all that apply)
1118	 Software
1119	 Electrical properties
1120	 Mechanical properties
1121	 Biologics
1122	Drugs
1123	 Coating(s) and surface modifications (e.g., an abraded material
1124	surface to encourage implant retention)
1125	 Single-use or multi-use
1126	 Single patient or multi-patient
1127	 Sterile or sterilization method [specify]
1128	 Energy source (if applicable)
1129	 This not only includes energy delivery to the device,
1130	including the use of batteries, but also energy delivery that is
1131	part of the functional aspect of the device (e.g., laser,
1132	radiofrequency, ultrasound, etc.).
1133	 Materials of use
1134	 Chemical formulation used in the materials of construction,
1135	especially for those materials that come into contact with the
1136	patient, should be provided.
1137	 Duration and type of contact
1138	 Other critical device features
1139	 These may include, but are not limited to, software/
1140	hardware features, density, porosity, degradation
1141	characteristics, nature of reagents (recombinant, plasma
1142	derived, etc.), principle of the assay method,
1143	manufacturing-related aspects, etc., that are not explicitly
1144	included as part of the materials, design or energy source
1145	characteristics.
1146	 If modifications are made to the device during the course of
1147	a study or between different stages of investigation (e.g.,
1148	early feasibility to pivotal), a detailed comparison of the
1149	original and modified device should be provided.
1150	

1151	APPENDIX D – GLOSSARY OF RISK MANAGEMENT TERMS ⁵⁰
1152	
1153	Terminology / Definitions – Risk Assessment
1154 1155	For the purposes of this guidance, terms are defined as follows:
1156	For the purposes of this guidance, terms are defined as follows.
1157	• Harm – physical injury or damage to the health of people, or damage to property or the
1158	environment.
1159	Hazard – potential source of harm
1160	• Risk – a combination of the probability of occurrence of harm and the severity of that
1161	harm. Note that in earlier stages of development a relative sense of likelihood may be
1162	used instead of probability of occurrence, which is difficult or impossible to estimate
1163	when little evidence is available.
1164	• Risk estimation – process used to assign values to the probability of occurrence of harm
1165	and the severity of harm
1166	• Risk analysis – systematic use of available information to identify hazards and to
1167	estimate the risk
1168	• Risk control – process in which decisions are made and measures implemented by which
1169	risks are reduced to, or maintained within, specified levels.
1170	• Residual risk – risk remaining after risk control measures have been taken
1171	

⁵⁰ Consistent with ISO 14971